Skip to main content

The development and validation of a novel COVID19 stigma scale among healthcare workers (COVISS-HCWs)


Background and aim

Fear of coronavirus disease 2019 (COVID-19) and its complications may result in stigmatization of individuals who may carry the virus. This is of special concern to healthcare workers who tolerate additional physical and emotional stress at times of pandemic. The aims of this study are to (1) develop and validate the COVID-19 Stigma Scale (COVISS-HCWs) survey; and (2) investigate the experience of stigma among healthcare workers possibly dealing with COVID-19 patients in five major public hospitals in Damascus, Syria.


We divided the sample into two parts and then underwent EFA on the first 350 participants, dividing the 14 questions into two dimensions. Furthermore, CFA was conducted on the other 350 participants to confirm how correctly a hypothesized model matched the factor structure by EFA, as described above. Moreover, the coefficient of determination (R2) and item–scale correlations (standardized factor loading) were estimated to establish the acceptability of the final structure of the COVISS-HCWs. Through a cross-sectional study, a convenience sample of 700 healthcare workers participated in a self-administered questionnaire containing a section for demographic variables and another for newly designed COVISS-HCWs. The scale comprises 14 adapted and novel items that measure two subscales: feelings of perceived harm and inferiority, and avoidance. Descriptive statistics, reliability, and validity were evaluated.


The 14 COVISS-HCWs items were reduced to 11 items with a high Cronbach’s α of 0.909. A significant correlation was observed between the responses to each COVISS-HCWs item and the corresponding subscale, and between each subscale and the overall scale. Feeling stigmatized was reported by 9.86% of the participants. Younger age, low socioeconomic status, and higher intensity of contact with COVID-19 patients significantly correlated with higher stigmatization.


The novel COVISS-HCWs is a reliable and valid tool to evaluate stigma among healthcare workers during the COVID-19 pandemic. The Stigma prevalence among healthcare workers was 9.86%. Therefore, this must be addressed to prevent possible psychosocial and public health repercussions.

Peer Review reports


The coronavirus disease which emerged in the year 2019, (COVID-19) is caused by the novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) [1]. The disease has assumed pandemic proportions leading to the death of over 6 million people worldwide [1]. Limited knowledge about the disease and lack of effective means of control may result in feelings of fear and anxiety of catching the infection, its symptoms, and complications. Fear of the disease may lead to negative behaviors against persons who have the disease or may have it [2]. Public health strategies dealing with rapidly growing disease outbreaks such as COVID-19 require a delicate balance between maintaining precautionary measures for infection control such as physical distancing while alleviating the possible psychological harms of such measures [3].

The psychological repercussions of lockdowns and physical distancing policies have been well documented [4]. These, however, may be aggravated by the stigma of carrying the infection or being around those who have it. According to the World Health Organization (WHO), stigma is defined as “the negative association between a person or group of people who share certain characteristics and a specific disease” [5]. Stigma might be expressed verbally or through discriminatory behaviors such as isolation, refusal to provide service, bullying, and harassment. Stigma may also affect individuals dealing with those infected with the disease, such as caregivers, family members, or those in the same community. Importantly, healthcare providers may also face stigmatization. This, along with the well-documented high rates of anxiety and depression among this group, may compromise their well-being and hence, may even threaten disease control [6]. Studying stigma against patients with infectious diseases such as human immunodeficiency virus (HIV), and tuberculosis (Tb) is prevalent. However, studies regarding stigma against healthcare providers taking care of those patients are limited. In March 2020, the WHO Department of Mental Health and Substance Use developed a series of suggestions that can be used to support the psychosocial well-being of different groups during the outbreak [7]. According to Roy et al., stigma is associated with many health conditions. In contrast, awareness may minimize the stigma and facilitate acceptance of the healthcare workers in the general population [7]. To date, only two studies documented stigmatization using a specific questionnaire against healthcare workers dealing with COVID-19 patients [8, 9]. The aim of this study is to design and validate a stigma scale specific to COVID-19 and investigate correlates of stigma among healthcare workers dealing with COVID-19 patients in Syria. Through a novel questionnaire tailored to the COVID-19 context, we studied feelings of perceived harm, shyness and inferiority, and avoidance among healthcare workers in five major public hospitals in Damascus, the capital of Syria. The validity and reliability of this questionnaire are presented in this manuscript. In addition, we aimed to investigate whether the experience of stigma correlates with demographic or workplace variables and whether it relates to a healthcare worker’s attitude towards COVID-19 vaccines.

Methods and materials

Study design and setting

This is a cross sectional study conducted in five primary public hospitals (Al Assad University Hospital, Al Mouwasat University Hospital, Children’s University Hospital, Dermatology University Hospital and Obstetrics University Hospital) that work with patients during COVID-19 pandemic in Damascus, Syria. Data was collected between August 1st and November 30th, 2020.

Ethical considerations

This study was approved by the institutional review board (IRB) of Damascus University with a protocol approval number of (613). All methods were performed in accordance with the relevant guidelines and regulations. The Questionnaire contained detailed information about the study objectives. Informed consent was first obtained from participants who volunteered to fill the questionnaire. The anonymity and confidentiality of the data were ensured by assigning an identification number to each participant restricted to the research team.

Sample selection

Healthcare workers (HCWs) were recruited through convenience sampling to participate in a self-administered questionnaire which was distributed by researchers via flyers. Respondents eligible for the study were adult male and female Syrian HCWs of at least 18 years of age. The sample included physicians, dentists, nurses, pharmacists, and other medical technicians who signed consent forms before data collection. In this study, the required number of participants ranged from 320 to 480 since the rule of thumb stated that 10–15 cases per candidate item are required. Therefore, the sample size of 700 participants included was adequate [10].

COVID-19 stigma scale development

A self-reported questionnaire was developed to determine if healthcare workers experienced COVID-19-related stigma, regardless of whether they were in direct contact with COVID-19 patients or not. A scientific committee consisting of physicians including three psychiatrists reviewed the literature pertaining to disease stigma and extracted some of the survey questions from previously validated surveys for other diseases such as the HIV, and TB stigma questionnaires [11,12,13,14,15,16]. The questions were then amended to suit the context of COVID-19. Newly created questions by the study committee were also added to the survey.

Measurement of demographics, stigma and correlates

The Questionnaire included three main parts: The first part consisted of eight questions regarding participant characteristics, including age in years, sex, place of residence, educational level, field of study, living status (flat, house, hostel), number of people living with the respondent, and financial status.

The second part of the questionnaire consisted of 14 questions Responses to each survey item was captured on a five-point Likert scale (1 = never, 2 = rarely, 3 = sometimes, 4 = very often, and 5 = always).

The third part of the questionnaire investigated aspects that may be related to stigmatization. The intensity of healthcare worker contact with COVID-19 patients was surveyed, and three responses were included: “no contact”; “only occasional contact for a few minutes with personal protective equipment (PPE)”; and “close daily contact with PPE”. Participants were also asked whether or not they had neighbors, relatives, or co-workers who were aware that they worked in hospitals or clinics, or that they were in contact with Coronavirus-infected individuals.

Moreover, the questionnaire investigated whether participants were willing to get a COVID-19 vaccine if it were to become available. The responses to this question included “I will not take it”; “I will take it without fear”; and “I will take it despite fear of its side effects”.

Data collection

A detailed explanation of the study was presented to healthcare workers at participating hospitals and clinics. The researchers distributed paper questionnaires directly to healthcare workers. Each questionnaire had a cover letter explaining the study, its aims, and how to complete and return the form. Participants had to sign consent forms and the self-completed questionnaires were returned to the researchers directly.

Statistical analysis

The Statistical Package for the Social Sciences (SPSS) software, version 23.0, was used for descriptive analysis. This included demographic characteristics of participants and frequency distributions of their responses to questionnaire items and to each subscale. The responses captured on a 1–5 scale were used to calculate means and standard deviations for each questionnaire item. Inferential statistics were conducted to test the correlations between stigma and different demographic variables. Chi-square test and post-hoc analysis using Tukey’s test where appropriate. The statistical significance level was set at (0.05).

Questionnaire reliability

Internal consistency reliability of the COVID-19 stigma Scale was measured by Cronbach’s alpha and corrected item-total correlations. A Cronbach’s alpha of 0.80 or higher implied acceptable reliability.

Questionnaire validity

A confirmatory factor analysis (CFA) was performed with maximum likelihood using AMOS version 23 data analysis software (Analysis of Moment Structures). Validation was conducted with a two-step approach was used. First: was dividing the sample into two parts then we underwent EFA on the first 350 participants. construct validity of the stigma scales was assessed we performed an EFA by a principal factor extraction method for the EFA cohort, with the factor obliquely rotated using the Promax criterion. The Kaiser-Meyer- Olkin measure and Bartlett test of sphericity were performed to ensure the appropriate use of factor analysis. Eigenvalues > 1.0 and the scree plot with the number of factors that explained > 5% of the variance were used to define the number of factors retained [17, 18]. To develop a practical and concise measurement tool we considered items acceptable if the loading coefficient was > 0.40.

The unidimensional set of items of the COVISS-HCWs was identified and underwent EFA which divided the 14 questions into two dimensions. The first dimension consisted of 10 questions while the second dimension consisted of 4 questions Table 1.

Table 1 Exploratory factor analysis of the 14-item stigma

To test the two-factor structure model of COVISS-HCWs, A CFA was conducted on the other 350 participants to confirm how correctly a hypothesized model matched the factor structure by EFA, as described above. CFA was performed with maximum likelihood using AMOS version 23 data analysis software (Analysis of Moment Structures).

To determine the appropriateness of the tested model, we tested the fit indices, including the root mean square error of approximation, standardized root mean square residual, comparative fit index, and Tucker-Lewis Index. Moreover, the coefficient of determination (R2) and item–scale correlations (standardized factor loading) were estimated to establish the acceptability of the final structure of the COVISS-HCWs. The CFA in turn excluded three questions from the questionnaire as their R-Squared was less than 0.30 Table 2. Finally, the questionnaire consisted of two subscales that included 11 items: the first subscale is harmfulness and inferiority (7 Items) while the second one is avoidance (4 Items).

Table 2 The Composite Reliability (CR) and Average Variance Extracted (AVE), and Discriminant Validity Index Summary for all Constructs

Cronbach’s α coefficient was calculated to determine the internal consistency reliability. The Cronbach’s α coefficient of the overall scale was 0.909, exceeding our minimum acceptable value of 0.8, which indicates an excellent level of internal consistency. The Cronbach’s α for the 2 subscales of harmfulness and inferiority, and avoidance were 0.87 (very good), and 0.85 (very good), respectively.

Using modification indices, significant cross-loadings were incorporated. These cross-loadings were determined to be measuring the same construct and were co-linear, so the higher loading variable of the pairs was retained to arrive at the final model. Model fit was assessed using Akaike Information Criterion (AIC) and Bayesian Information Criterion (BIC), and convergent and divergent validity were evaluated.


Characteristics of study participants

In analyzing the demographic characteristics of the study sample (Table 3), we found that most participants were between 18–29 years old (79.4%), females (61.6%), and living in Damascus (67.7%). Moreover, most were living in a family house (57%), in medium (38.6%) and good (46.6%) socioeconomic status and holding advanced degrees (62.9%). While most participants were working in internal medicine departments (44.7%), 20.6% were working in the nursing departments, and smaller percentages were working in other medical departments.

Table 3 Characteristics of study participants

Responses of healthcare workers to stigma question

Responses were captured on 1–5 Likert scale. The average response to each survey item was calculated to evaluate the most common responses. We found that the mean response of every item in all subscales was above 1.0 and less than 3.0. However, the spread in responses was relatively wide with standard deviations of mean ranging between 0.43—1.39 (Table 4).

Table 4 Reliability of COVID19 sigma scale

Participants more frequently responded with “never” or “rarely” to the questionnaire items with percentages ranging between 6%—91.8% of the participants. Also, participants less frequently (0%—18.1%) responded with “very often” or “always”. This confirms that many participants reported experiencing some form of harmfulness and inferiority, and avoidance.

Internal consistency reliability of COVID19 stigma scale

Table 7 presents our findings on COVID Stigma Scale reliability. The Cronbach’s α coefficient of the overall scale was 0.909, exceeding our minimum acceptable value of 0.8, which indicates an excellent level of internal consistency. The Cronbach’s α for the 2 subscales of harmfulness and inferiority, and avoidance were 0.87 (very good), and 0.85 (very good), respectively.

Moreover, we found a corrected item total correlation range of 0.214—0.717. With most items of the questionnaire meeting a minimum corrected item-total correlation of 0.3, and none of the items having negative correlations, this points to very good internal consistency.

Validity of COVID19 stigma scale

To evaluate construct validity, Pearson’s correlation coefficients between the responses of each subscale and the responses of the whole stigma scale, and also between the two subscales were calculated. Correlation coefficients between the subscales (r = 0.651), and between the subscales and the overall scale (r = 0.858 – 0.949) were all significant (all P-values < 0.001), indicating that survey items work in harmony to measure COVID19 stigma with good level of validity (Table 5). Additionally, the responses to each item significantly correlated with its corresponding subscale (all P-values < 0.001). Pearson’s correlations ranged between 0.71—0.81 in the Harmfulness and inferiority, and 0.82- 0.85 in the avoidance subscale. Taken together, these data indicate that COVISS-HCWs items serve its purpose with good internal validity. Corrected item-total correlations of 0.30 were used as indicators of internal consistency reliability [19].

Table 5 Pearson’s correlations between the responses to each subscale and the overall scale

The final CFA model

The final model did not achieve non-significance, indicating that the global model did not reproduce the observed covariances among the 11 items very well. However, this is common and likely due to the small sample size and ordinal nature of the factors, which are not parametric. Thus, we also evaluated other measures of model fit, as shown in Table 6. The root mean square error (RMSE) improved with each iteration of the model, with the final model at 0.062, which is considered acceptable (i.e., well below the 0.080 cutoff) and is an improvement over the original model. In addition, the comparative fit index (CFI) improved as the model was refined, and the final value of 0.971 is close to the upper limit of this measure (1.00), indicating good model fit. The standardized root means square residual (SRMR) decreased across model iterations, with the final model below the cutoff of 0.1 (Table 6).

Table 6 Model Fit Statistics for COVISS-HCWs

Table 7 demonstrates that all factors in the final model loaded highly and significantly onto their theoretical constructs, indicating that the survey items are all important indicators of the theoretical constructs (latent factors), as theorized.

Table 7 Standardized factor loadings, p-values, 95% Cis, and R2 for survey items in the final model for COVISS-HCWs

In the Harmfulness and Inferiority Subscale, the survey item that explained the largest proportion of variance (65.6%) was Q3, while for the Avoidance Subscale, Q9 explained the largest proportion of variance (69.8%). Thus, the COVISS-HCWs survey is a reliable and valid measure of Perceived Harmfulness and Inferiority, and Avoidance. The items in these subscales are strongly related to the latent variables (Perceived Harmfulness and Inferiority, and Avoidance) as specified, and can be utilized for assessing the same in HCWs.

Confirmatory factor analysis resulted in reducing the survey from 14 to 11 items (Table 7).

For the final model, convergent validity was explored using average variance extracted (AVE)and composite reliability (CR). A model is generally regarded as having acceptable convergent validity if the AVE is at least 0.50 and the composite reliability CR is above 0.70.

Referring to Table 4, the CR for all constructs is above 0.70 and the AVE values are greater than 0.50. The discriminant validity was assessed using Fornel and Larcker (1971) by comparing the square root of each AVE in the diagonal with the correlation coefficients (off-diagonal) for each construct in the relevant rows and columns. However, the square root of the AVE for Factor was greater than the absolute value of the correlation with another factor. Overall, convergent and discriminant validity can be accepted for this measurement model and the final model is presented in Fig. 1.

Fig. 1
figure 1

Final CFA Model for COVISS-HCWs

Frequency of stigmatization among healthcare workers

We summarized participants’ responses to each COVISS-HCWs item into no stigma for those who answered with “never” and “rarely”; neutral for “sometimes”; and stigma for “very often” and “always”. Frequency distribution of stigma experience is presented in Table 8. For each subscale and COVISS-HCWs, the mean number of participants and their percentage under each stigma category was calculated. Our findings indicate that 9.86% of the participants reported being stigmatized. Harmfulness and inferiority, and avoidance were experienced by 10.43% and 9.30% of the participating healthcare workers, respectively.

Table 8 Descriptive analysis based on stigmatization

Moreover, we used Chi-square test to evaluate the distribution of responses into demographic variables. The results indicate that age significantly correlated with the presence of COVID-19 stigma (P < 0.001), with a higher percentage of participants between the age of 18–29 years reporting stigmatization. Moreover, financial status significantly correlated with experiencing stigma (P = 0.013), with a higher percentage of low-income participants feeling stigmatized (32.3%), as opposed to 15.7%, 14.3%, and 12.9% of participants of medium, good, and excellent financial status, respectively, indicating a dose response relationship. No significant association was reported between medical specialty and stigmatization frequency.

Most participants (80.4%) had neighbors, relatives, or co-workers who were aware that they worked in hospitals or clinics, or that they were in contact with Coronavirus-infected individuals (81.5%). And most participants (96.6%) had occasional or close/daily contact with COVID-19 patients. Importantly, the intensity of contact with SARS-CoV2-infected people correlated positively with stigmatization (P = 0.004), as 19.4% of those who were in close daily contact compared to 14.6% of those who only had occasional contact felt stigmatized. On the other hand, only 7.5% of those who had no contact with COVID-19 patients reported feeling stigmatized.

Stigmatization correlates with COVID-19 vaccine attitudes among healthcare workers

We hypothesized that stigmatization increases the likelihood of accepting a vaccine that protects them from COVID-19. The attitudes of healthcare workers towards the upcoming SARS-Cov2 vaccines were investigated; where 25.7% said they would not take it, 40.9% said they would take it despite being fearful of its possible side effects, and 27.1% said they would take the vaccine without fear. The rest of the participants (6.3%) did not respond to this question.

Interestingly, we found that SARS-Cov2 vaccine attitudes significantly correlated with feeling stigmatized (P < 0.001). While 69.8% and 73% of those in the “no stigma” and “neutral” categories reported they will take the vaccine, 83.6% of participants in the “stigma” category stated they will take the vaccine. Additionally, among the participants who said they will take the vaccine despite fear of its side effects, 21.9% felt stigmatized, while 14.5% of those who stated they will take the vaccine without fear, and only 10.2% of those who stated they will not take the vaccine felt stigmatized. These data suggest that those who feel stigmatized may find a way out of their situation through vaccination, even if they had fears around a new vaccine. This, however, needs further investigation.


Stigma develops towards diseases in situations where a person is considered to be the cause of disease, incurable or degenerative, when the disease seems to cause adverse effects for others, and when it has visible signs on the patient’s body. These situations are compatible with many diseases such as tuberculosis, leprosy, HIV/AIDS, H1N1 and severe acute respiratory syndrome (SARS). During the SARS outbreak, HCWs were prevented from interacting outside and inside the hospital with their colleagues. Furthermore, habits that require mask removal such as eating, and drinking were done alone or outside the hospital [20]. In addition, HCWs had concerns about their safety, transmitting the disease to family members, stigmatization, and social isolation. On the other hand, the relationship between patients and staff became blurred as they experienced a strong emotional identification with their colleagues who were now infected which increased anxiety regarding their competence and skills [20]. One study reported that HCWs realize that their work is less valued due to the stigma that comes from close dealing with HIV-infected patients [21]. While currently, during the COVID-19 pandemic, HCWs in Mexico and Malawi were found to use bicycles, as they were prevented from using public transportation and were subjected to physical abuse [22]. In India, doctors and nurses dealing with COVID-19 patients faced social stigmatization as they were fired from their rented homes and were even attacked during their duties [22]. Recently, COVID-19 joined the list of diseases that trigger stigmatization. However, this disease has different pathologies and spreads relatively faster than many other diseases, which is likely to cause more panic among community members. As in the case with previous outbreaks, HCWs during COVID-19 are at the frontline confronting the pandemic and may face stigmatization. Experiencing stigma negatively affects HCWsʼ psychological status which may reflect on their medical performance and influences the spread of disease. According to the WHO, HCWs treating COVID-19 are considered as a stigma-vulnerable group during the pandemic along with travelers to infected countries and symptomatic patients [23, 24]. Considering the widespread nature and continuing relevance of COVID-19 and its associated stigma, it is important to develop a COVID-19-specific stigma scale in order to evaluate the prevalence of stigma during the pandemic. A universal, reliable, and valid scale for evaluating presence of COVID-19 stigma among HCWs is still lacking. The main objective of the current study, that included 700 HCWs from five of Damascus’s dedicated COVID-19 hospitals, was to develop the COVID-19 Stigma Scale (COVISS-HCWs) in order to investigate the prevalence of COVID-19-associated stigma among HCWs and its possible predictive factors. Accordingly, we developed and divided COVISS-HCWs items into two subscales (harmfulness, and inferiority, and avoidance) depending on EFA. Confirmatory factor analysis (CFA) resulted in reducing COVISS from 14 to 11 items. Importantly, responses to all items and all subscales highly correlated with the overall scale indicating COVISS-HCWs reliability. We found that 69 HCW (9.86% were stigmatized according to our validated score. Few studies reported varying proportions of COVID-19 stigma using non-validated stigma tools among Indonesian, Egyptian, Burkina Faso, Nigerian, and Ethiopian physicians that were 21.9%, 31.2%, 66%, 67%, and 88% respectively [25,26,27]. Furthermore, Adalberto et al. suggested non- validated scale to determine COVID-19 stigma-discrimination toward HCWs [28]. In general, studies that attempted to use a definite validate COVID-19 stigma scale involved either non-HCWs such as general population and recovered infected patients or a particular group of HCWs except the Vietnamese and Egyptian studies [9, 29,30,31,32].The later attempted to adapt the SARS stigma scale to form a valid scale for assessing the presence of covid-19 among physicians [9].

The scale consists of 16-item, each item had four possible responses distributed as 1–4 Likert scale points, allocated into three subscales personalized stigma (8 items); concerns of disclosure and public attitudes (5 items); and negative experiences (3 items) with Cronbach’s α for the three subscales 0.90, 0.66, and 0.78 respectively and 0.90 for overall scale [9]. In this study, we adapted some questions from Nyblade HIV and TB stigma scales to fit Covid 19 HCWs [11, 12].Whereas, the other questions were developed by our team to Covid 19 HCWs. Our final novel questionnaire consists of 11 items only, each item had five possible responses and distributed as 1–5 Likert scale points which is more precise than 1–4 Likert scale points, allocated into two subscales harmfulness and inferiority (7 items); and avoidance (4 items) with Cronbach’s α for the two subscales 0.87 (very good), and 0.85 (very good), respectively and 0.909 for overall scale. The Egyptian study depends on the SARS stigma scale that developed its scale from Berger HIV scale which is developed to assess stigma among infected HIV patients not particularly to assess stigma among HCWs [9, 33, 34]. While we adapted some questions from Nyblade HIV and TB stigma scales that designed their scales to assess stigma among HCWs [11, 12]. Another small study included only 61 Vietnamese HCWs attempted to develop validated scale that administrated in Vietnamese language, while in this study the scale was administrated in English language to increase its utility in the world [32]. However, the published scale was different from the SARS HIV and tuberculosis stigma scale which we used to develop the COVISS-HCWs scale [11, 12, 33]. The first subscale concerns harmfulness and inferiority, and the second subscale was avoidance faced by HCWs due to communication behaviors. Responses to all items and all subscales highly correlated with the overall scale. Further analysis of validity measures allow us to conclude that the final model displayed good convergent but mixed divergent validity [35]. In this study, financial status significantly correlated with experiencing stigma as it appears in 32,3% of low-income participants, which is nearly similar to other studies conducted in low-income countries (37%) [36]. This can be explained that low-income countries are more likely to attend stress and as a result they may have huge psychological pressure on population as well as HCWs. In addition, HCWs who have less contact with COVID-19 patients were less stigmatized than others who had occasional contact, and also less than who had daily close contact with them, 7.5%, 14.6% and 19.4% respectively. This result is similar to other studies which end up with 3.5 times stigmatization when HCWs deal with COVID-19 inpatients [25]. Stigma aggravates stress, post-traumatic stress syndrome, burnout syndrome, inability to concentrate and make decisions, negative self-image and concerns about the public attitude in addition to feeling guilty and avoiding communication with friends and family members [4, 32, 37,38,39]. As a result, inability to work properly and cope with the various situations was seen in the presence of HCWs stigmatization and mental health damage [40, 41]. Our findings show that HCWs are being stigmatized and need to have help from health policy makers and officials. Moreover, it is essential to provide effective psychiatric, physical, ethical and social support from their families, friends and health professionals after quarantine or hospitalization to get over the negative consequences. This may reduce the long-term mental effects of the disease [42].

Study strengths and limitations

This is the first validated scale to evaluate COVID19 stigma rates among health care workers using only 11-items. The scale was adapted from others that were specifically developed and validated for HCWs, with additional questions that we tailored to fit the COVID19 context. However, our study is cross-sectional, hence it demonstrated associations but not causal relations between the studied elements. It was also based on a self-reported questionnaire, not direct observation. Therefore, responder bias cannot be excluded, and findings may be biased by social desirability to prove HCWs distress during the pandemic. Moreover, resident doctors represented the vast majority of our specimen which may represent a specific group of HCWs, and thus may limit the generalizability of our findings to all HCWs.


Stigma towards HCWs in COVID-19 pandemic is a widespread phenomenon in countries all over the world. It should be identified with its categories harmfulness and inferiority, and avoidance. 9.86% of HCWs were stigmatized. COVISS-HCWs demonstrated very good internal consistency and construct validity among this sample of Syrian's HCWs. These satisfactory properties make the COVISS-HCWs suitable for utilize by health care providers.

Availability of data and materials

The datasets generated during and analyzed during the current study are not publicly available due to containing information that could compromise the privacy of research participants but are available from the corresponding author on reasonable request.


  1. World Health Organization. Coronavirus Disease (COVID-19) Situation Reports. Accessed 4 February 2022..

  2. Turner-Musa J, Ajayi O, Kemp L. Examining social determinants of health, stigma, and COVID-19 Disparities. Healthcare (Basel). 2020;8(2):168.

    Article  PubMed  Google Scholar 

  3. Person B, Sy F, Holton K, Govert B, Liang A. Fear and stigma: the epidemic within the SARS outbreak. Emerg Infect Dis. 2004;10(2):358–63.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Singh S, Roy D, Sinha K, Parveen S, Sharma G, Joshi G. Impact of COVID-19 and lockdown on mental health of children and adolescents: a narrative review with recommendations. Psychiatry Res. 2020;293:113429.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. World Health Organization. A guide to preventing and addressing social stigma associated with COVID-19. Accessed 2 February 2022.

  6. Earnshaw VA, Quinn DM. The impact of stigma in healthcare on people living with chronic illnesses. J Health Psychol. 2012;17(2):157–68.

    Article  PubMed  Google Scholar 

  7. Roy D, Tripathy S, Kar SK, Sharma N, Verma SK, Kaushal V. Study of knowledge, attitude, anxiety & perceived mental healthcare need in Indian population during COVID-19 pandemic. Asian J Psychiatr. 2020;51: 102083.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Tsukuda M, Ito Y, Nojima K, Kayano T, Honda J, Health P. Development and Validation of the COVID-19-Related Stigma Scale for Healthcare Workers (CSS-HCWs). Int J Environ Res Public Health. 2022;19(15):9641.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. Mostafa A, Mostafa NS, Ismail N. Validity and reliability of a COVID-19 stigma scale using exploratory and confirmatory factor analysis in a sample of Egyptian Physicians: E16-COVID19-S. Int J Environ Res Public Health. 2021;18(10):5451.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Tabachnick B, Fidell LJUMS, 4th ed. Allyn, Bacon B, MA. Using Multivariate Statistics, Allyn and Bacon, Boston, MA. 2001:-.

  11. Nyblade L, Jain A, Benkirane M, Li L, Lohiniva AL, McLean R, et al. A brief, standardized tool for measuring HIV-related stigma among health facility staff: results of field testing in China, Dominica, Egypt, Kenya, Puerto Rico and St. Christopher & Nevis. Journal of the International AIDS Society. 2013;16(3 Suppl 2):18718.

  12. Craig G, Meershoek A, Zwerling A, Daftary A, Citro B, Smyth C, et al. TB STIGMA–MEASUREMENT GUIDANCE. 2018.

  13. Jones ACJJoC, RD-CMR MR. Stigma and shame: Conceptualisations and views concerning service use and health care provision: A literature review and commentary. 2019;10012.

  14. Link BG, Phelan JC, Sullivan G. Mental and physical health consequences of the stigma associated with mental illnesses. The Oxford handbook of stigma, discrimination, and health2018.

  15. Abiri S, Oakley LD, Hitchcock ME, Hall A. Stigma related avoidance in people living with severe mental illness (SMI): findings of an integrative review. Community Ment Health J. 2016;52(3):251–61.

    Article  PubMed  Google Scholar 

  16. Ben-Zeev D, Young MA, Corrigan PW. DSM-V and the stigma of mental illness. J Ment Health (Abingdon, England). 2010;19(4):318–27.

    Article  Google Scholar 

  17. Norris M, Lecavalier L. Evaluating the use of exploratory factor analysis in developmental disability psychological research. J Autism Dev Disord. 2010;40(1):8–20.

    Article  PubMed  Google Scholar 

  18. Roberson RB, Elliott TR, Chang JE, Hill JN. Exploratory factor analysis in Rehabilitation Psychology: a content analysis. Rehabil Psychol. 2014;59(4):429–38.

    Article  PubMed  Google Scholar 

  19. Nunnally JC. Psychometric theory 3E: Tata McGraw-hill education; 1994.

  20. Maunder R, Hunter J, Vincent L, Bennett J, Peladeau N, Leszcz M, et al. The immediate psychological and occupational impact of the 2003 SARS outbreak in a teaching hospital. CMAJ. 2003;168(10):1245–51.

    PubMed  PubMed Central  Google Scholar 

  21. Siegel J, Yassi A, Rau A, Buxton JA, Wouters E, Engelbrecht MC, et al. Workplace interventions to reduce HIV and TB stigma among health care workers–where do we go from here? Glob Public Health. 2015;10(8):995–1007.

    Article  PubMed  Google Scholar 

  22. Bagcchi S. Stigma during the COVID-19 pandemic. Lancet Infect Dis. 2020;20(7):782.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. World Health Organization. WHO Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020. Accessed 1 February 2022.

  24. Korte K, Denckla C, Ametaj A, Koenen K. Viruses don't discriminate and neither should we. Retrieved from Harvard University at. harvard. edu/student-life; 2020.

  25. Yufika A, Pratama R, Anwar S, Winardi W, Librianty N, Prashanti NAP, et al. Stigma Associated with COVID-19 Among Health Care Workers in Indonesia. Disaster medicine and public health preparedness. 2021:1–5.

  26. Mostafa A, Sabry W, Mostafa NS. COVID-19-related stigmatization among a sample of Egyptian healthcare workers. PLoS ONE. 2020;15(12): e0244172.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  27. Assefa N, Soura A, Hemler EC, Korte ML, Wang D, Abdullahi YY, et al. COVID-19 knowledge, perception, preventive measures, stigma, and mental health among healthcare workers in Three Sub-Saharan African Countries: a phone survey. Am J Trop Med Hyg. 2021;105(2):342–50.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  28. Campo-Arias A, Álvarez-Solorza I, Tirado-Otálvaro AF, Cassiani-Miranda CA. Proposal of a scale for COVID-19 stigma-discrimination toward health workers. J Investig Med. 2021;69(1):100–1.

    Article  PubMed  Google Scholar 

  29. Nochaiwong S, Ruengorn C, Awiphan R, Kanjanarat P, Ruanta Y, Phosuya C, et al. COVID-19 public stigma scale (COVID-PSS): development, validation, psychometric analysis and interpretation. BMJ Open. 2021;11(11): e048241.

    Article  PubMed  Google Scholar 

  30. Al-Zamel LA, Al-Thunayan SF, Al-Rasheed AA, Alkathiri MA, Alamri F, Alqahtani F, et al. Validation and cultural adaptation of explanatory model interview catalogue (EMIC) in Assessing stigma among recovered patients with COVID-19 in Saudi Arabia. Int J Environ Res Public Health. 2021;18(16):8261.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  31. Uvais NA, Aziz F, Hafeeq B. COVID-19-related stigma and perceived stress among dialysis staff. J Nephrol. 2020;33(6):1121–2.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  32. Do Duy C, Nong VM, Van Ngo A, Doan Thu T, Do Thu N, Nguyen QT. COVID-19-related stigma and its association with mental health of health-care workers after quarantine in Vietnam. Psychiatry Clin Neurosci. 2020;74(10):566–8.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Verma S, Mythily S, Chan YH, Deslypere JP, Teo EK, Chong SA. Post-SARS psychological morbidity and stigma among general practitioners and traditional Chinese medicine practitioners in Singapore. Ann Acad Med Singapore. 2004;33(6):743–8.

    PubMed  CAS  Google Scholar 

  34. Berger BE, Ferrans CE, Lashley FR. Measuring stigma in people with HIV: psychometric assessment of the HIV stigma scale. Res Nurs Health. 2001;24(6):518–29.

    Article  PubMed  CAS  Google Scholar 

  35. Mehmetoglu M. CONDISC: Stata module to perform convergent and discriminant validity assessment in CFA. Statistical Software Components S458003. Boston College Department of Economics.: Stata; 2015.

  36. Yuan K, Huang XL, Yan W, Zhang YX, Gong YM, Su SZ, et al. A systematic review and meta-analysis on the prevalence of stigma in infectious diseases, including COVID-19: a call to action. Mol Psychiatry. 2022;27(1):19–33.

    Article  PubMed  CAS  Google Scholar 

  37. Chew QH, Chia FL-A, Ng WK, Lee WCI, Tan PLL, Wong CS, et al. Psychological and coping responses to COVID-19 amongst residents in training across ACGME-I accredited specialties in Singapore. Psychiatry Res. 2020;290:113146-.

  38. Chew NWS, Lee GKH, Tan BYQ, Jing M, Goh Y, Ngiam NJH, et al. A multinational, multicentre study on the psychological outcomes and associated physical symptoms amongst healthcare workers during COVID-19 outbreak. Brain Behav Immun. 2020;88:559–65.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  39. Tan BYQ, Chew NWS, Lee GKH, Jing M, Goh Y, Yeo LLL, et al. Psychological Impact of the COVID-19 Pandemic on Health Care Workers in Singapore. Ann Intern Med. 2020;173(4):317–20.

    Article  PubMed  Google Scholar 

  40. Bao Y, Sun Y, Meng S, Shi J, Lu L. 2019-nCoV epidemic: address mental health care to empower society. Lancet (London, England). 2020;395(10224):e37–8.

    Article  PubMed  CAS  Google Scholar 

  41. Holmes EA, O’Connor RC, Perry VH, Tracey I, Wessely S, Arseneault L, et al. Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health science. The lancet Psychiatry. 2020;7(6):547–60.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Unicef. Social stigma associated with the coronavirus disease (COVID-19). Accessed 1 January 2022

Download references


Not applicable.


No funding source was used to support this work.

Author information

Authors and Affiliations



HNA, AA, HA, and YL designed the questionnaire. HNA, AA, HA, and ANA collected the data. RTA and MM conducted the descriptive analysis and prepared the relevant tables. MM and DA performed reliability tests. RTA interpreted the analysis, wrote the abstract, methods and results sections, and edited the introduction. DA and HNA performed the EFA and CFA analysis, prepared the relevant tables and the figure, and wrote parts of the methods and results. CESJ performed the CFA analysis, prepared the relevant tables, and wrote parts of the methods and results. HNA, HA, AA and ANA wrote the introduction and discussion. All the authors approved the final manuscript.

Corresponding author

Correspondence to Hasan Nabil Al Houri.

Ethics declarations

Ethics approval and consent to participate

This study was approved by the institutional review board (IRB) of Damascus University with a protocol approval number of (613). Informed consent was first obtained from participants who volunteered to fill the questionnaire. All methods were performed in accordance with the relevant guidelines and regulations.

Consent for publication

Not applicable.

Competing interests

The authors declare no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Al Houri, H.N., Alhouri, A., Akasheh, R.T. et al. The development and validation of a novel COVID19 stigma scale among healthcare workers (COVISS-HCWs). BMC Health Serv Res 22, 1481 (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: